Skip to content

Journal · Real-world drug outcomes · Updated 22 November 2026

Drugs – Real World Outcomes

Read Drugs – Real World Outcomes articles on DeepDyve. No university library needed.

Drugs – Real World Outcomes covers how medicines work and how safe they are in everyday practice, from observational studies of blood pressure and pulmonary hypertension treatments to analyses of adverse event reports and drug interactions in hospitals. Springer Nature publishes it, and it has published since 2014. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Drugs - Real World Outcomes
Journal cover

Drugs – Real World Outcomes at a glance

Full title
Drugs – Real World Outcomes
Abbreviation (NLM)
Drugs Real World Outcomes
Publisher
Springer Nature
Print ISSN
2199-1154
Online ISSN (eISSN)
2198-9788
First published
2014
Access model
Open access since 2014

Ways to access Drugs – Real World Outcomes

All of the articles Drugs – Real World Outcomes published from January 1 to November 20, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 100% of Drugs – Real World Outcomes articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Drugs – Real World Outcomes. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Drugs – Real World Outcomes articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Drugs – Real World Outcomes’ 2025 Journal Impact Factor is 2.0, and its 5-year Impact Factor is 2.1.

2.0

Journal Impact Factor (2025)

2.1

5-year Impact Factor (2025)

6 days

Median time to first decision

Source: journal metrics on the Drugs – Real World Outcomes homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Drugs – Real World Outcomes research worth reading

Published January to June 2026. Summaries describe what the authors report.

  1. Open accessPulmonary hypertension · Selexipag

    Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)

    Analyzing 894 adults starting selexipag in the SPHERE and EXPOSURE observational studies, the authors report that over half began almost 3 years after diagnosis, and that 1-year survival ranged from 100% in low-risk to 59% in high-risk patients.

    Escribano Subias et al. · Drugs – Real World Outcomes, published online January 12, 2026 · DOI 10.1007/s40801-025-00536-4

  2. Open accessPharmacovigilance · Diabetes drugs

    Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan

    Searching Japan’s adverse drug event reports, the authors identified 2175 pemphigoid events linked to DPP-4 inhibitors, most often vildagliptin, and report that yearly events rose from 30 in 2015 to a peak of 412 in 2018 after package insert precautions were revised.

    Takami et al. · Drugs – Real World Outcomes, published online January 12, 2026 · DOI 10.1007/s40801-025-00535-5

  3. Open accessPharmacovigilance · Hemp products

    Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades

    Analyzing 1712 FDA adverse event reports involving hemp products from 2004 to 2025, the authors report that seizures, anxiety and depression were most strongly associated with hemp, with risks differing by age and higher for women for nearly all reactions except seizures.

    Teng et al. · Drugs – Real World Outcomes, published online February 11, 2026 · DOI 10.1007/s40801-026-00542-0

  4. Open accessDrug interactions · Pulmonary medicine

    Assessment of Potential Drug–Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study

    Studying 377 pulmonary inpatients at a tertiary care hospital in Nepal, the authors report that Lexicomp flagged potential drug–drug interactions in 36.1% and Micromedex in 19.9%, with polypharmacy, longer stays, comorbidities, alcohol use and older age linked to higher risk.

    Dangi et al. · Drugs – Real World Outcomes, published online June 25, 2026 · DOI 10.1007/s40801-026-00563-9

  5. Open accessHypertension · Combination therapy

    Evaluation of Effectiveness and Safety of Telmisartan and Amlodipine Fixed-Dose Combination in Indian Patients with Hypertension: TACT-India Study

    In an observational study of 6232 Indian patients with hypertension, the authors report that a telmisartan and amlodipine fixed-dose combination lowered mean systolic blood pressure from 155.12 to 135.96 mmHg over 8 weeks, with around 70% reaching target blood pressure.

    Das et al. · Drugs – Real World Outcomes, published online January 5, 2026 · DOI 10.1007/s40801-025-00534-6

See every Drugs – Real World Outcomes article on DeepDyve

Questions about Drugs – Real World Outcomes

How can I read Drugs – Real World Outcomes articles without a subscription?

100% of Drugs – Real World Outcomes articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Drugs – Real World Outcomes articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Drugs – Real World Outcomes?

Drugs – Real World Outcomes’ NLM (PubMed) abbreviation is Drugs Real World Outcomes.

What is the ISSN of Drugs – Real World Outcomes?

The print ISSN is 2199-1154 and the online ISSN is 2198-9788.

What is the impact factor of Drugs – Real World Outcomes?

Drugs – Real World Outcomes’ Journal Impact Factor is 2.0 (2025), and its 5-year Impact Factor is 2.1, according to Springer Nature’s published metrics.

Is Drugs – Real World Outcomes open access?

Yes. Drugs – Real World Outcomes has published open access since 2014: 60 of the 60 articles it published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref.

Drugs – Real World Outcomes articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.

Start reading Drugs – Real World Outcomes today

One month free, then less than $2 a day. Drugs – Real World Outcomes, plus millions of articles from thousands of journals.

Start free month

Like this: